Inovio Pharmaceuticals (NASDAQ:INO) Issues Earnings Results, Misses Expectations By $0.09 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.09), RTT News reports. Inovio Pharmaceuticals had a negative return on equity of 88.13% and a negative net margin of 16,238.91%. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. During the same period in the prior year, the firm posted ($1.56) EPS.

Inovio Pharmaceuticals Stock Performance

Shares of INO stock opened at $8.44 on Monday. The company has a market capitalization of $218.69 million, a PE ratio of -2.63 and a beta of 0.89. Inovio Pharmaceuticals has a 52-week low of $3.89 and a 52-week high of $14.75. The business’s fifty day moving average is $9.49 and its 200 day moving average is $10.33.

Analysts Set New Price Targets

Several analysts have recently issued reports on INO shares. Royal Bank of Canada lowered their price target on shares of Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating on the stock in a research report on Friday. Stephens began coverage on Inovio Pharmaceuticals in a report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, HC Wainwright reiterated a “neutral” rating and set a $15.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $47.00.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.